Impact of Survival Rate and Safety Analysis of Concurrent Chemoradiotherapy in Patients with Recurrent Cervical Cancer

Objective: To investigate the effect of concurrent chemoradiotherapy on the survival rate and safety of patients with recurrent cervical cancer. Methods: A total of 107 patients with recurrent cervical cancer who were treated in our hospital from March 2016 to January 2019 were retrospectively analyzed and randomly divided into the control group (n = 53) and the observation group (n = 54) and treated conventionally. On this basis, the control group was treated with radiotherapy, and the observation group was treated with concurrent radiotherapy and chemotherapy. The clinical efficacy, cellular immune index, survival rate and rate of adverse reactions were compared between the two groups. Results: Compared with the total effective rate of 79.25% in the control group, the observation group was 94.44%, and the difference was statistically significant(P<0.05). After treatment, the levels of NK, CD3+, and CD4+ in the two groups were higher than before the treatment, and the observation group was higher than the control group. The difference was statistically significant (P<0.05). Compared with the adverse reaction rate of 18.87% in the control group, the observation group was 11.11%, but the difference was not statistically significant (P>0.05). Conclusion: Concurrent chemoradiotherapy for patients with recurrent cervical cancer has a significant effect, which not only can effectively improve the cellular immune index and the survival rate of patients, but also have high safety.